High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis

Human Pathology

Volumn 37, Issue 7, 2006, Pages 906-913

  Kim, Tae Joong ^a   Rho, Seung Bae ^a   Choi, Yoon La ^a   Choi, Chel Hun ^a   Lee, Jeong Won ^a   Bae, Duk Soo ^a   Ahn, Geunghwan ^a   Lee, Je Ho ^a   Kim, Byoung Gie ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

MMP 2; Ovarian neoplasms; Serous tumor; TIMP 2

Indexed keywords

GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL GROWTH; CLINICAL ARTICLE; CYSTADENOMA; ENZYME ACTIVATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; OVARY TUMOR; PLASMID; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; CYSTADENOMA, SEROUS; FEMALE; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFECTION;

EID: 33745131373     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.02.017     Document Type: Article

References (31)

1. Vihinen P., and Kahari V.M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99 (2002) 157-166
2. Seo D.W., Li H., Guedez L., et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114 (2003) 171-180
3. Denhardt D.T., Feng B., Edwards D.R., et al. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 59 (1993) 329-341
4. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 (2002) 2387-2392
5. Baker A.H., Edwards D.R., and Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115 (2002) 3719-3727
6. Jiang Y., Goldberg I.D., and Shi Y.E. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21 (2002) 2245-2252
7. Brew K., Dinakarpandian D., and Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477 (2000) 267-283
8. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17 (2001) 463-516
9. Stetler-Stevenson W.G., Bersch N., and Golde D.W. Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett 296 (1992) 231-234
10. Murphy A.N., Unsworth E.J., and Stetler-Stevenson W.G. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 157 (1993) 351-358
11. Brand K., Baker A.H., Perez-Canto A., et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res 60 (2000) 5723-5730
12. Valente P., Fassina G., Melchiori A., et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 75 (1998) 246-253
13. Hoegy S.E., Oh H.R., Corcoran M.L., et al. Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J Biol Chem 276 (2001) 3203-3214
14. Sakata K., Shigemasa K., Nagai N., et al. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 17 (2000) 673-681
15. Okamoto T., Niu R., and Yamada S. Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary. Mol Hum Reprod 9 (2003) 569-575
16. Kikkawa F., Tamakoshi K., Nawa A., et al. Positive correlation between inhibitors of matrix metalloproteinase 1 and matrix metalloproteinases in malignant ovarian tumor tissues. Cancer Lett 120 (1997) 109-115
17. Furuya M., Ishikura H., Kawarada Y., et al. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms. Gynecol Oncol 78 (2000) 106-112
18. Davidson B., Goldberg I., Gotlieb W.H., et al. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol 187 (2002) 39-45
19. Davidson B., Goldberg I., Gotlieb W.H., et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 17 (1999) 799-808
20. Roebuck M.M., Helliwell T.R., Chaudhry I.H., et al. Matrix metalloproteinase expression is related to angiogenesis and histologic grade in spindle cell soft tissue neoplasms of the extremities. Am J Clin Pathol 123 (2005) 405-414
21. Ozen O., Krebs B., Hemmerlein B., et al. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance. Clin Cancer Res 10 (2004) 4746-4753
22. Tunuguntla R., Ripley D., Sang Q.X., et al. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer. Gynecol Oncol 89 (2003) 453-459
23. Asha Nair S., Karunagaran D., Nair M.B., et al. Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J Cancer Res Clin Oncol 129 (2003) 123-131
24. Yoshida H., Ishiko O., Sumi T., et al. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol 19 (1999) 537-542
25. Davidson B., Reich R., Berner A., et al. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer 37 (2001) 2040-2049
26. Remacle A., McCarthy K., Noel A., et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 89 (2000) 118-121
27. Davidson B., Goldberg I., Kopolovic J., et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma-a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 73 (1999) 372-382
28. Grignon D.J., Sakr W., Toth M., et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 56 (1996) 1654-1659
29. Schmalfeldt B., Prechtel D., Harting K., et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 7 (2001) 2396-2404
30. Lengyel E., Schmalfeldt B., Konik E., et al. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 82 (2001) 291-298
31. Yoshizaki T., Maruyama Y., Sato H., et al. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer 95 (2001) 44-50